A PHASE 1, MULTICENTER, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY OF SQZ-PBMC-HPV AS MONOTHERAPY AND IN COMBINATION WITH ATEZOLIZUMAB IN HLA-A*02+ PATIENTS WITH HPV16+ RECURRENT, LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
- Registry ID
- SQZ-PBMC-HPV-101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- SQZ BIOTECHNOLOGIES
- Start date
- 2021-11-22
- Last update
- 2020-02-14
Conditions
- ADVANCED SOLID TUMORS
- METASTATIC SOLID TUMOURS
Related clinical trials
- A PHASE II, MULTI-CENTER, MASTER PROTOCOL TO EVALUATE THE EFFICACY AND SAFETY OF VOLRUSTOMIG AS MONOTHERAPY OR IN COMBINATION WITH ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED/METASTATIC SOLID TUMORS
- A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF GSK5533524 ALONE OR IN COMBINATION WITH OTHER ANTI-CANCER AGENTS, IN ADULT PARTICIPANTS WITH SELECTED ADVANCED SOLID TUMORS
- A PHASE 1, 2-PART, MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF THE ANTI-LY6E EXATECAN ANTIBODY-DRUG CONJUGATE M7437 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
- A PHASE 1/2A, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PRELIMINARY EFFICACY OF BMS-986523 AS MONOTHERAPY AND IN COMBINATION WITH ANTI-CANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID MALIGNANCIES
- A PHASE 1 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF NDI-219216 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SOLID TUMORS WITH AND WITHOUT MICROSATELLITE INSTABILITY AND/OR DEFICIENT MISMATCH REPAIR
- A PHASE 1B/2 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF GSK5764227 IN COMBINATION WITH STANDARD OF CARE (SOC) OR OTHER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
View on source registry